Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

The aim of this international guideline on dementia was to present a peer‐reviewed evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. It covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician. The main focus is Alzheimer's disease, but many of the recommendations apply to dementia disorders in general. The task force working group considered and classified evidence from original research reports, meta‐analysis, and systematic reviews, published before January 2006. The evidence was classified and consensus recommendations graded according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. The recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, genetic testing, tissue biopsy, disclosure of diagnosis, treatment of Alzheimer's disease, and counselling and support for caregivers were all revised when compared with the previous EFNS guideline. New recommendations were added for the treatment of vascular dementia, Parkinson's disease dementia, and dementia with Lewy bodies, for monitoring treatment, for treatment of behavioural and psychological symptoms in dementia, and for legal issues. The specialist physician plays an important role together with primary care physicians in the multidisciplinary dementia teams, which have been established throughout Europe. This guideline may contribute to the definition of the role of the specialist physician in providing dementia health care.

[1]  Bridget Kelly,et al.  A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. , 1998, Archives of neurology.

[2]  A. Mackinnon,et al.  Combining cognitive testing and informant report to increase accuracy in screening for dementia. , 1998, The American journal of psychiatry.

[3]  Lo J. Bour,et al.  Slowing on Quantitative Spectral EEG Is a Marker for Rate of Subsequent Cognitive and Functional Decline in Early Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[4]  C. Colosimo,et al.  Donepezil in the treatment of progressive supranuclear palsy , 2001, Acta neurologica Scandinavica.

[5]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[6]  S. Coons,et al.  Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. , 2005 .

[7]  H. Nelson A Modified Card Sorting Test Sensitive to Frontal Lobe Defects , 1976, Cortex.

[8]  A Drzezga,et al.  Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration , 2002, Neurology.

[9]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[10]  C. Ballard,et al.  Atypical antipsychotics for aggression and psychosis in Alzheimer's disease , 2006 .

[11]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[12]  L. Schneider,et al.  Estrogen levels do not correlate with improvement in cognition. , 2003, Archives of neurology.

[13]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[14]  J. Cummings,et al.  Alzheimer's disease and related disorders annual , 2000 .

[15]  L. Schneider,et al.  Memantine for dementia. , 2006, The Cochrane database of systematic reviews.

[16]  J. Wiltfang,et al.  Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.

[17]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[18]  A. Nordberg,et al.  Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer’s disease , 2000, Neurobiology of Aging.

[19]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[20]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[21]  M. De Hert,et al.  Cost of disorders of the brain in Europe. , 2006, European journal of neurology.

[22]  D. Gifford,et al.  Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. , 2000, Archives of internal medicine.

[23]  Turan M. Itil,et al.  A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .

[24]  Sasha Bozeat,et al.  Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[25]  B. Steinhoff,et al.  Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. , 1996, Archives of neurology.

[26]  G. Wilcock,et al.  Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial , 2004, European journal of neurology.

[27]  D. Sparks,et al.  Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. , 2005, Current Alzheimer Research.

[28]  L. Bellak,et al.  Geriatric psychiatry : a handbook for psychiatrists and primary care physicians , 1976 .

[29]  H. Yamanouchi,et al.  Access www.neurology.org now for full-text articles , 2001, Neurology.

[30]  B. Boeve,et al.  Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy , 2001, Movement disorders : official journal of the Movement Disorder Society.

[31]  Z Walker,et al.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.

[32]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[33]  C. Berr,et al.  Cost of dementia in Europe , 2005, European journal of neurology.

[34]  Frederik Barkhof,et al.  Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study , 2003, Stroke.

[35]  K. Blennow,et al.  CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.

[36]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[37]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[38]  C. K. Y. Chan,et al.  Screening for Dementia: A Preliminary Study on the Validity of the Chinese Version of the Blessed-Roth Dementia Scale , 2003 .

[39]  A. Schatzberg,et al.  A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. , 1997, JAMA.

[40]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[41]  A. Crawley,et al.  Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  Ove Almkvist,et al.  Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease , 1999 .

[43]  J. Orgogozo,et al.  Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.

[44]  Diederick E Grobbee,et al.  Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study , 1995, BMJ.

[45]  P Julin,et al.  Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[46]  J. Martín,et al.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[47]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[48]  N. Waugh,et al.  Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. , 2001, Health technology assessment.

[49]  Paul Duberstein,et al.  How effective are interventions with caregivers? An updated meta-analysis. , 2002, The Gerontologist.

[50]  L. Flicker,et al.  Piracetam for dementia or cognitive impairment. , 2004, The Cochrane database of systematic reviews.

[51]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[52]  M. Albert,et al.  Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. , 1993, Archives of neurology.

[53]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[54]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.

[55]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[56]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.

[57]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[58]  M. Hallett,et al.  Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy , 2001, Neurology.

[59]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[60]  K. Davis,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[61]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[62]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[63]  B. Oken Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[64]  Jean-Claude Baron,et al.  Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.

[65]  H. Wiśniewski,et al.  In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[66]  B. Seltzer,et al.  Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.

[67]  D. Bereczki,et al.  The Cochrane Database of Systematic Reviews , 2003 .

[68]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[69]  C Jonker,et al.  The diagnostic value of electroencephalography in mild senile Alzheimer's disease , 1999, Clinical Neurophysiology.

[70]  W. Herrmann,et al.  Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. , 1997, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[71]  V. Hachinski,et al.  Electroencephalography as an aid in the exclusion of Alzheimer's disease. , 1994, Archives of neurology.

[72]  F Barkhof,et al.  The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m‐HMPAO Single‐Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community‐Dwelling Elderly Population , 1997, Alzheimer disease and associated disorders.

[73]  M. McDonagh,et al.  A Systematic Review of the Efficacy and Safety of Atypical Antipsychotics in Patients with Psychological and Behavioral Symptoms of Dementia , 2006, Journal of the American Geriatrics Society.

[74]  C. Schweiger [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[75]  J. Ridley Studies of Interference in Serial Verbal Reactions , 2001 .

[76]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[77]  Nick C Fox,et al.  Rates of global and regional cerebral atrophy in AD and frontotemporal dementia , 2001, Neurology.

[78]  B. Sahakian,et al.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.

[79]  G. Samsa,et al.  Alzheimer disease: operating characteristics of PET--a meta-analysis. , 2004, Radiology.

[80]  G. Frisoni,et al.  Linear measures of atrophy in mild Alzheimer disease. , 1996, AJNR. American journal of neuroradiology.

[81]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[82]  P. Harper,et al.  Genetic testing for Huntington's disease. , 1990, BMJ.

[83]  J. Cummings Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[84]  C. Hirsch Alzheimer's Disease: A Physician's Guide to Practical Management , 2004 .

[85]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[86]  L. Candelise,et al.  Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.

[87]  J. López-arrieta,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2000, The Cochrane database of systematic reviews.

[88]  U. Salvolini,et al.  Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimer’s Disease , 1998, European Neurology.

[89]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[90]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[91]  M. Ebell Donepezil in the treatment of vascular dementia. , 2004, American family physician.

[92]  Philip Scheltens,et al.  Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry , 1999, Psychiatry Research: Neuroimaging.

[93]  L. Flicker,et al.  Selegiline for Alzheimer's disease. , 2003, The Cochrane database of systematic reviews.

[94]  C. Mariani,et al.  Observations on dementias with possibly reversible symptoms , 1999, Aging.

[95]  J T O'Brien,et al.  Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment , 1997, Psychological Medicine.

[96]  Jacob Cohen,et al.  A comprehensive support program: effect on depression in spouse-caregivers of AD patients. , 1995, The Gerontologist.

[97]  G. Wilcock,et al.  A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.

[98]  A. Spector,et al.  Aspirin for vascular dementia. , 2000, The Cochrane database of systematic reviews.

[99]  G. Small,et al.  An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. , 2003, Clinical therapeutics.

[100]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[101]  Barry Horwitz,et al.  Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type , 1995, Psychiatry Research.

[102]  P. Cras,et al.  Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. , 1999, Journal of Alzheimer's disease : JAD.

[103]  G C Roman,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[104]  G. Foster,et al.  THE USE OF CT SCANNING IN DEMENTIA , 1999, International Journal of Technology Assessment in Health Care.

[105]  K. Laake,et al.  Statins for the reduction of risk of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.

[106]  P. Scheltens,et al.  Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.

[107]  J. Hodges,et al.  Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. , 1992, Brain : a journal of neurology.

[108]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[109]  H. Wiśniewski,et al.  Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer's Disease , 1997, International Psychogeriatrics.

[110]  A. W. Lemstra,et al.  Een klinisch algoritme voor het gebruik van de 14-3-3-liquortest bij de diagnostiek van de ziekte van Creutzfeldt-Jakob , 2001 .

[111]  A. Boxer,et al.  Clinical Features of Frontotemporal Dementia , 2005, Alzheimer disease and associated disorders.

[112]  G. Livingston,et al.  How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis , 2000, International journal of geriatric psychiatry.

[113]  I. McKeith,et al.  Behavioural changes and psychological symptoms in dementia disorders , 2005, The Lancet Neurology.

[114]  S. Ferris,et al.  An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. , 1993, The Gerontologist.

[115]  T. McRae,et al.  Comments on Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.

[116]  G. Wilcock,et al.  Clinical utility of computed tomography in the assessment of dementia: a memory clinic study , 2004, International journal of geriatric psychiatry.

[117]  J. Hodges,et al.  Transient epileptic amnesia: a description of the clinical and neuropsychological features in 10 cases and a review of the literature , 1998, Journal of neurology, neurosurgery, and psychiatry.

[118]  A. Wallin,et al.  The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia , 2000, Journal of the Neurological Sciences.

[119]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[120]  B. Vellas,et al.  Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.

[121]  Anthony F Jorm Methods of Screening for Dementia: A Meta‐Analysis of Studies Comparing an Informant Questionnaire with a Brief Cognitive Test , 1997, Alzheimer disease and associated disorders.

[122]  L. Schneider,et al.  A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[123]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[124]  K Masaki,et al.  Practice parameter: Risk of driving and Alzheimer’s disease , 2001, Neurology.

[125]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[126]  A. Colchester,et al.  MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. , 2001, Clinical radiology.

[127]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[128]  C. Marra,et al.  Effects of aging and of Alzheimer's disease on verbal memory. , 1995, Journal of clinical and experimental neuropsychology.

[129]  N. Qizilbash Evidence based dementia practice , 2002 .

[130]  B. Lebowitz,et al.  Behavioral and Psychological Symptoms of Dementia: A Clinical and Research Update , 2000, International Psychogeriatrics.

[131]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[132]  H C Liu,et al.  Effects of estrogen on cognition, mood, and cerebral blood flow in AD , 2000, Neurology.

[133]  N. Tabet,et al.  Vitamin E for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.

[134]  R. Petersen,et al.  Frequency of tau mutations in three series of non‐Alzheimer's degenerative dementia , 1999, Annals of neurology.

[135]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[136]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[137]  T. Erkinjuntti,et al.  Usefulness of the Clinical Dementia Rating Scale in Screening for Dementia , 1995, International Psychogeriatrics.

[138]  G Lundberg,et al.  The Swedish National Road Administration , 1996 .

[139]  M. Philpot,et al.  Functional Imaging in Dementia , 1989 .

[140]  T. Dening,et al.  Antidepressants for treating depression in dementia. , 2002, The Cochrane database of systematic reviews.

[141]  A. C. Stein,et al.  Practice parameter: Risk of driving and Alzheimer’s disease (an evidence-based review) , 2000, Neurology.

[142]  A. Stöffler,et al.  New Approaches to Clinical Trials in Vascular Dementia: Memantine in Small Vessel Disease , 2002, Cerebrovascular Diseases.

[143]  R. Görtelmeyer,et al.  Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. , 1992, Arzneimittel-Forschung.

[144]  M. Fioravanti,et al.  Nicergoline for dementia and other age associated forms of cognitive impairment , 2001 .

[145]  K. Laake,et al.  Statins for the prevention of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.

[146]  P. Knipschild,et al.  Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. , 2003, Journal of clinical epidemiology.

[147]  Arthur L. Benton,et al.  Differential behavioral effects in frontal lobe disease , 1968 .

[148]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[149]  H. Budka,et al.  Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.

[150]  I. Zerr,et al.  Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. , 2000, Archives of neurology.

[151]  A. M. Clarfield,et al.  The decreasing prevalence of reversible dementias: an updated meta-analysis. , 2003, Archives of internal medicine.

[152]  P. Scheltens,et al.  CSF tau and Aβ42 are not useful in the diagnosis of frontotemporal lobar degeneration , 2004, Neurology.

[153]  Bruce L. Miller,et al.  Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .

[154]  R. Reitan Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[155]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[156]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[157]  Henry Brodaty,et al.  Meta‐Analysis of Psychosocial Interventions for Caregivers of People with Dementia , 2003, Journal of the American Geriatrics Society.

[158]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[159]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[160]  J. Birks,et al.  Donepezil for vascular cognitive impairment. , 2004, The Cochrane database of systematic reviews.

[161]  B L Miller,et al.  Estrogen for Alzheimer’s disease in women , 2000, Neurology.

[162]  F. Baas,et al.  [Clinical algorithm for cerebrospinal fluid test of 14-3-3 protein in diagnosis of Creutzfeldt-Jacob disease]. , 2001, Nederlands tijdschrift voor geneeskunde.

[163]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[164]  J. Touchon,et al.  Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period , 2005, Current medical research and opinion.

[165]  J. O'Brien,et al.  Volumetric and visual assessment of the mesial temporal structures in Alzheimer's disease. , 1994, Australian and New Zealand journal of medicine.

[166]  J. Vanneste,et al.  Diagnosis and management of normal-pressure hydrocephalus , 2000, Journal of Neurology.

[167]  I. McKeith A Physician’s Guide to Practical Management , 2005 .

[168]  G. McGwin,et al.  Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.

[169]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[170]  J. Cummings,et al.  Comorbidity in dementia: an autopsy study. , 2004, Archives of pathology & laboratory medicine.

[171]  M. Rossor,et al.  EEG abnormalities in frontotemporal lobar degeneration , 2004, Neurology.

[172]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[173]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[174]  J. Luxenberg,et al.  Valproic acid for agitation in dementia. , 2002 .

[175]  Nick C Fox,et al.  Epilepsy presenting as AD: Neuroimaging, electroclinical features, and response to treatment , 2002, Neurology.

[176]  Klaus P. Ebmeier,et al.  Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[177]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[178]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[179]  M. Michalopoulou,et al.  Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[180]  I. Zalonis,et al.  CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population , 2003, European journal of neurology.

[181]  K. Yaffe,et al.  Hormone replacement therapy to maintain cognitive function in women with dementia. , 2009, The Cochrane database of systematic reviews.

[182]  K. Ishii,et al.  Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. , 2000, Radiology.

[183]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[184]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[185]  J. Luxenberg,et al.  Haloperidol for agitation in dementia. , 2002, The Cochrane database of systematic reviews.

[186]  J. Duchek,et al.  Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. , 1997, Archives of neurology.

[187]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[188]  T. Hope,et al.  Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD) , 1996, British Journal of Psychiatry.

[189]  Marina Boccardi,et al.  The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia , 2003, Neurobiology of Aging.

[190]  S H Ferris,et al.  Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. , 1987, The Journal of clinical psychiatry.

[191]  C. Callahan,et al.  The Efficacy of Pentoxifylline in the Treatment of Vascular Dementia: A Systematic Review , 2003, Alzheimer disease and associated disorders.

[192]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[193]  J. Cummings,et al.  Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease , 2004 .

[194]  P. Scheltens,et al.  Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.

[195]  J. Corey-Bloom,et al.  Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[196]  E. Perry,et al.  Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial , 2000, International journal of geriatric psychiatry.

[197]  J. Birks,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.

[198]  I. Bone,et al.  Diagnostic strategies in CADASIL , 2003, Neurology.

[199]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[200]  P. Lantos,et al.  Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies , 1999, British Journal of Psychiatry.

[201]  Gwenn S. Smith,et al.  EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.

[202]  Rachelle Doody,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[203]  Norman Sartorius,et al.  Access to diagnostic evaluation and treatment for dementia in Europe , 2007, International journal of geriatric psychiatry.

[204]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[205]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[206]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[207]  L. Wilkins Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[208]  J. Olesen,et al.  The burden of brain diseases in Europe , 2003, European journal of neurology.

[209]  J. Swartz,et al.  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.

[210]  H C Liu,et al.  The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening tool for dementia for a predominantly illiterate chinese population , 1995, Neurology.

[211]  G. Waldemar,et al.  Potentially reversible conditions in 1000 consecutive memory clinic patients , 2002, Journal of neurology, neurosurgery, and psychiatry.

[212]  J. O’Brien,et al.  Treating behavioural and psychological signs in Alzheimer's disease , 1999, BMJ.

[213]  C. Ballard,et al.  The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. , 2002, The Cochrane database of systematic reviews.

[214]  M. Verbeek,et al.  Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases , 2003, Annals of clinical biochemistry.

[215]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[216]  M. Rossor,et al.  Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine , 2005, Neurology.

[217]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[218]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[219]  D. Richards,et al.  A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia , 2001, Aging & mental health.

[220]  H J Sagar,et al.  Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. , 1992, Brain : a journal of neurology.

[221]  S. Salloway,et al.  Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial , 2003, Stroke.

[222]  Anthony F Jorm,et al.  The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms , 1989, Psychological Medicine.

[223]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[224]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[225]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[226]  J. Argente,et al.  Insulin-like growth factor I, insulin-like growth factor binding proteins, and growth hormone binding protein in Spanish premature and full-term newborns. , 1996, Hormone research.

[227]  K. Ditzler Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.

[228]  B. Sahakian,et al.  Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia , 2001, Journal of neurology, neurosurgery, and psychiatry.

[229]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[230]  R. S. Doody, MD, PhD,et al.  Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[231]  Ann Marie Hake,et al.  The use of memantine in dementia with Lewy bodies. , 2005, Journal of Alzheimer's disease : JAD.

[232]  Serge Gauthier,et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.

[233]  H Merskey,et al.  Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. , 1993, Archives of neurology.

[234]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[235]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[236]  J. Cummings,et al.  Prevalence and impact of medical comorbidity in Alzheimer's disease. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[237]  K. Johansson,et al.  The 1994 International Consensus Conference on Dementia and Driving: A Brief Report , 1997, Alzheimer disease and associated disorders.

[238]  H J Testa,et al.  Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia , 2002, Acta neurologica Scandinavica.

[239]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[240]  K. Blennow,et al.  Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations , 2001, Experimental Neurology.

[241]  B. Winblad,et al.  3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy , 2006, Dementia and Geriatric Cognitive Disorders.

[242]  D. Davies,et al.  MYOCARDIAL DISORDERS IN THE ELDERLY. , 1963, Lancet.

[243]  J. Wiltfang,et al.  Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.

[244]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[245]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[246]  Desmond O’Neill,et al.  Health and Relicensing Policies for Older Drivers in the European Union , 2000, Gerontology.

[247]  Dag Aarsland,et al.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.

[248]  K. Blennow,et al.  Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia , 2002, Dementia and Geriatric Cognitive Disorders.

[249]  J. Birks,et al.  Ginkgo biloba for cognitive impairment and dementia. , 2007, The Cochrane database of systematic reviews.

[250]  J. Birks,et al.  Ginkgo biloba for cognitive impairment and dementia (Review) , 2017 .

[251]  B. Dubois,et al.  ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. , 2002, Presse medicale.

[252]  W F Stewart,et al.  Screening for dementia with the Memory Impairment Screen , 1999, Neurology.

[253]  L. Schneider,et al.  Galantamine for Alzheimer's disease and mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[254]  R DeJong,et al.  Measurement of quality-of-life changes in patients with Alzheimer's disease. , 1989, Clinical therapeutics.

[255]  K. Yaffe,et al.  Hormone replacement therapy to maintain cognitive function in women with dementia. , 2002, The Cochrane database of systematic reviews.

[256]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[257]  B. Steinhoff,et al.  How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. , 1999, Brain : a journal of neurology.

[258]  P. Scheltens,et al.  Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. , 2000, European journal of neurology.

[259]  D. Craig,et al.  Galantamine for vascular cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[260]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[261]  Dag Aarsland,et al.  Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.

[262]  T. del Ser,et al.  Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia: A Randomized Placebo-Controlled Trial , 2005, Stroke.

[263]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[264]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[265]  O. Gefeller,et al.  Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease , 1998, Annals of neurology.

[266]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[267]  Bruno Dubois,et al.  Testing cognition may contribute to the diagnosis of movement disorders , 1996, Neurology.

[268]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[269]  J. Woo,et al.  Age of Onset and Brain Atrophy in Alzheimer's Disease , 1997, International Psychogeriatrics.

[270]  I G McKeith,et al.  Medial temporal lobe atrophy on MRI in dementia with Lewy bodies , 1999, Neurology.

[271]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[272]  H. Christensen,et al.  Improving screening accuracy for dementia in a community sample by augmenting cognitive testing with informant report. , 2003, Journal of clinical epidemiology.

[273]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[274]  Charles DeCarli,et al.  Radial width of the temporal horn: a sensitive measure in Alzheimer disease. , 2002, AJNR. American journal of neuroradiology.